HBO Kennisbank

3 Resultaten

Sorteer op:

Zocht je misschien: barf, calls, cell?

The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients

Zwierenga, Fenneke; Dijkhuizen, Christa (Biomolecules & Health); Korthuis, Patrick; Timens, Wim; Groen, Harry; Hiltermann, Jeroen; van den Berg, Anke; Drayer, Lyndsay; van der Wekken, Anthonie

Clinical outcomes in ROS1-fusion positive (ROS1+) non-small cell lung cancer (NSCLC) by fusion partner and resistance mechanisms are limited. This cohort study included 56 ROS1+ patients (FISH or NGS confirmed); fusion partners were identified in 27 cases, including CD74 (n = 10), EZR (n = 7), and SDC4 …

2025-08-29GezondheidArtikel

L2026M+G2032R variant confers resistance to ROS1 tyrosine kinase inhibitors in SCL34A2-ROS1 overexpressing Ba/F3 cells through a reduced ATP binding pocket volume

Dijkhuizen, Christa (Biomolecules & Health); Korthuis, Patrick; Vilachã, Juliana F.; Smelt, Maaike; van der Wekken, Anthonie; van den Berg, Anke; Drayer, Lyndsay

Background The ROS1 G2032R mutation is the most common on-target resistance mutation in crizotinib treated ROS1-positive lung cancer patients. The aim of our study was to investigate resistance mechanisms in SCL34A2-ROS1G2032R positive Ba/F3 cells against second line treatment with lorlatinib. Methods …

2023-10-21GezondheidConferentiebijdrage

SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume

Dijkhuizen, Christa (Biomolecules & Health); Korthuis, Patrick; Vilachã, Juliana F.; Smelt, Maaike; van der Wekken, Anthonie; van den Berg, Anke; Drayer, Lyndsay

2023GezondheidConferentiebijdrage

Vorige Volgende

The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients

L2026M+G2032R variant confers resistance to ROS1 tyrosine kinase inhibitors in SCL34A2-ROS1 overexpressing Ba/F3 cells through a reduced ATP binding pocket volume

SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume

Over HBO Kennisbank